PT1937065E - Novos sais de lisina de derivados ácido 4-((fenoxialquil)tio)-fenoxiacético - Google Patents

Novos sais de lisina de derivados ácido 4-((fenoxialquil)tio)-fenoxiacético Download PDF

Info

Publication number
PT1937065E
PT1937065E PT06803483T PT06803483T PT1937065E PT 1937065 E PT1937065 E PT 1937065E PT 06803483 T PT06803483 T PT 06803483T PT 06803483 T PT06803483 T PT 06803483T PT 1937065 E PT1937065 E PT 1937065E
Authority
PT
Portugal
Prior art keywords
phenoxialquil
fenoxiacético
tio
lysine salts
new lysine
Prior art date
Application number
PT06803483T
Other languages
English (en)
Portuguese (pt)
Inventor
Ahmed F Abdel-Magid
Steven J Mehrman
Armin Roessler
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT1937065E publication Critical patent/PT1937065E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT06803483T 2005-09-14 2006-09-13 Novos sais de lisina de derivados ácido 4-((fenoxialquil)tio)-fenoxiacético PT1937065E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71713705P 2005-09-14 2005-09-14

Publications (1)

Publication Number Publication Date
PT1937065E true PT1937065E (pt) 2015-03-04

Family

ID=37865545

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06803483T PT1937065E (pt) 2005-09-14 2006-09-13 Novos sais de lisina de derivados ácido 4-((fenoxialquil)tio)-fenoxiacético

Country Status (30)

Country Link
US (2) US7709682B2 (enExample)
EP (1) EP1937065B1 (enExample)
JP (1) JP5467770B2 (enExample)
KR (5) KR20180079468A (enExample)
CN (1) CN101304656B (enExample)
AR (1) AR058044A1 (enExample)
AU (1) AU2006291006B2 (enExample)
BE (1) BE2025C533I2 (enExample)
BR (1) BRPI0615835B8 (enExample)
CA (1) CA2622722C (enExample)
CY (1) CY2025023I1 (enExample)
DK (1) DK1937065T3 (enExample)
ES (1) ES2535427T3 (enExample)
FI (1) FIC20253005I1 (enExample)
FR (1) FR25C1030I2 (enExample)
GT (1) GT200600420A (enExample)
HN (1) HN2006032171A (enExample)
HU (2) HUE025185T2 (enExample)
JO (1) JO3006B1 (enExample)
LT (1) LTC1937065I2 (enExample)
LU (1) LUC50018I2 (enExample)
NL (1) NL301339I2 (enExample)
NZ (1) NZ566504A (enExample)
PE (1) PE20070434A1 (enExample)
PL (1) PL1937065T3 (enExample)
PT (1) PT1937065E (enExample)
SI (1) SI1937065T1 (enExample)
TW (1) TWI414510B (enExample)
UY (1) UY29791A1 (enExample)
WO (1) WO2007033231A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100877B1 (en) * 2003-09-19 2012-01-25 Janssen Pharmaceutica N.V. 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs
HUE028213T2 (en) 2003-09-19 2016-12-28 Janssen Pharmaceutica Nv 4 - ((Phenoxyalkyl) thio) -phenoxyacetic acid for use in the treatment of PPAR-delta-mediated conditions
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
UY30288A1 (es) * 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
BRPI0920170A2 (pt) 2008-10-17 2016-06-21 Metabolex Inc métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
US20160016982A1 (en) * 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
DK2459176T3 (en) 2009-07-31 2017-12-04 Gruenenthal Gmbh Crystallization process and bioavailability
DK2531200T3 (en) * 2010-02-06 2017-09-11 Gruenenthal Gmbh COSTALLIZATION PROCEDURE AND BIOTA ACCESSIBILITY
AU2011296737A1 (en) 2010-08-31 2013-04-11 Snu R&Db Foundation Use of the fetal reprogramming of a PPAR delta agonist
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
WO2015077154A1 (en) 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
US20160279085A1 (en) * 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
HRP20181914T1 (hr) 2014-03-20 2019-01-11 Cymabay Therapeutics, Inc. Liječenje intrahepatičnih kolestatskih bolesti
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
SG11201608077PA (en) 2014-04-11 2016-10-28 Cymabay Therapeutics Inc Treatment of nafld and nash
MX2016017081A (es) * 2014-06-26 2017-05-01 Cymabay Therapeutics Inc Tratamiento de hipertrigliceridemia grave.
CN109415323A (zh) * 2016-05-16 2019-03-01 普尔玛根治疗(哮喘)有限公司 喹啉衍生物的结晶
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN111093705A (zh) 2017-09-13 2020-05-01 诺华股份有限公司 包含fxr激动剂的组合
SI3973959T1 (sl) 2017-09-26 2025-03-31 Cymabay Therapeutics, Inc. Zdravljenje holestatskega pruritusa s seladelparjem
EP3880187A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
EP3880185A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Combination treatment of nafld and nash
EP4034236A1 (en) 2019-09-26 2022-08-03 Abionyx Pharma SA Compounds useful for treating liver diseases
US20210145774A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
CN119735532A (zh) * 2019-11-21 2025-04-01 杭州百诚医药科技股份有限公司 α-氟代查耳酮类衍生物及其应用
AU2022214948B2 (en) 2021-02-01 2023-07-13 Cymabay Therapeutics, Inc. Treatment of cholangiopathies with seladelpar
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2024159048A1 (en) 2023-01-29 2024-08-02 Cymabay Therapeutics, Inc. Treatment of uremic pruritus
AU2024212873A1 (en) 2023-01-29 2025-08-07 Cymabay Therapeutics, Inc. Treatment of chronic pruritic dermatoses
CN118546109A (zh) * 2023-02-24 2024-08-27 哈尔滨三联药业股份有限公司 含氮杂环类化合物及其医药用途
WO2025072489A2 (en) 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
WO2026030479A1 (en) * 2024-07-31 2026-02-05 Cymabay Therapeutics, Inc. Process for making seladelpar
US20260060948A1 (en) 2024-07-31 2026-03-05 Cymabay Therapeutics, Inc. Methods for treating liver disease

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460689C3 (de) 1974-12-20 1980-06-26 Klinge Pharma Gmbh & Co, 8000 Muenchen 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4125732A (en) 1977-05-06 1978-11-14 American Cyanamid Company 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters
DE3026924A1 (de) 1980-07-16 1982-02-18 Klinge Pharma GmbH & Co, 8000 München 1,3-diphenoxypropan-2-ol-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3028776A1 (de) 1980-07-29 1982-02-25 Klinge Pharma GmbH & Co, 8000 München Neue 1,3-diphenoxypropan-2-on-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP0056172B1 (en) 1981-01-09 1985-04-03 FISONS plc Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them
JPS58177934A (ja) 1982-04-13 1983-10-18 Takeda Chem Ind Ltd ベンゾキノン誘導体
EP0106565B1 (en) 1982-09-30 1986-09-10 Merck Frosst Canada Inc. Leukotriene antagonists, their production, and compositions containing them
US4820867A (en) * 1983-04-21 1989-04-11 Merck Frosst Canada, Inc. Phenoxypropoxy halophenylacetic acids as leukotriene antagonists
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
JPS61268651A (ja) 1985-05-23 1986-11-28 Takeda Chem Ind Ltd フエニル酢酸誘導体およびその製造法
EP0204349A3 (de) 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH0714910B2 (ja) * 1988-12-13 1995-02-22 塩野義製薬株式会社 安定な結晶性の塩およびそれを含有するトロンボキサン受容体拮抗剤
US5487008A (en) 1990-04-20 1996-01-23 The Regents Of The University Of Michigan Method and system for detecting the misfire of a reciprocating internal combustion engine in frequency domain
CA2092152A1 (en) * 1992-03-23 1993-09-24 Azuma Igarashi Phenoxyacetic acid compounds and medical preparations containing them
US5726165A (en) 1994-07-29 1998-03-10 Smithkline Beecham P.L.C. Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
EP1011651B1 (en) 1996-02-02 2005-04-27 Merck & Co., Inc. Method of treating diabetes and related disease states
DE69723680T9 (de) 1996-02-02 2004-11-04 Merck & Co., Inc. Antidiabetische mittel
JP3268242B2 (ja) 1996-11-14 2002-03-25 三共株式会社 縮合複素環化合物を含有する医薬
ES2320181T3 (es) 1997-07-24 2009-05-19 Astellas Pharma Inc. Composiciones farmaceuticas que tienen un efecto reductor del colesterol.
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
NZ529351A (en) 2001-06-07 2006-01-27 Lilly Co Eli Modulators of peroxisome proliferator activated receptors
CZ2004133A3 (cs) 2001-07-30 2004-06-16 Novo Nordisk A/S Deriváty vinylkarboxylové kyseliny, farmaceutický prostředek ho obsahující a jeho použití
AU2002323776B2 (en) 2001-08-10 2008-07-31 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-responsive receptor Delta
JP4276074B2 (ja) 2001-10-12 2009-06-10 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
ITRM20020014A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
EP1480957A1 (en) 2002-03-01 2004-12-01 Smithkline Beecham Corporation Hppars activators
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
PL375700A1 (en) * 2002-09-05 2005-12-12 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
ATE469882T1 (de) * 2002-10-28 2010-06-15 High Point Pharmaceuticals Llc Neue verbindungen, die sich f r die behandlung von durch ppar vermittelten krankheiten eignen
MXPA05004402A (es) * 2002-10-28 2005-07-26 Novo Nordisk As Compuestos novedosos y su uso como moduladores de receptores activados por proliferador de peroxisoma.
EP1594955B1 (en) 2003-02-14 2012-04-11 Biogen Idec MA Inc. An expression cassette and vector for transient or stable expression of exogenous molecules
WO2005019151A1 (en) 2003-08-20 2005-03-03 Eli Lilly And Company Ppar modulators
EP2100877B1 (en) * 2003-09-19 2012-01-25 Janssen Pharmaceutica N.V. 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs
HUE028213T2 (en) 2003-09-19 2016-12-28 Janssen Pharmaceutica Nv 4 - ((Phenoxyalkyl) thio) -phenoxyacetic acid for use in the treatment of PPAR-delta-mediated conditions
CN1897939A (zh) 2003-10-31 2007-01-17 詹森药业有限公司 适用作过氧化物酶体增生物激活受体（ppar）双重激动剂的苯氧基乙酸衍生物
KR20060135901A (ko) 2004-04-21 2006-12-29 쉐링 코포레이션 피라졸로-[4,3-ｅ]-1,2,4-트리아졸로-[1,5-ｃ]피리미딘아데노신 Ａ2ａ 수용체 길항제
KR100843028B1 (ko) 2004-07-01 2008-07-01 에프. 호프만-라 로슈 아게 아세틸렌기를 포함하는 페닐 유도체
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY145712A (en) 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0618963D0 (en) 2006-09-26 2006-11-08 Ucl Business Plc Formulations and composites with reactive fillers

Also Published As

Publication number Publication date
PL1937065T3 (pl) 2015-07-31
LTC1937065I2 (enExample) 2025-12-29
ES2535427T3 (es) 2015-05-11
KR20130100800A (ko) 2013-09-11
PE20070434A1 (es) 2007-05-14
CN101304656B (zh) 2013-03-13
JO3006B1 (ar) 2016-09-05
FR25C1030I1 (fr) 2025-09-26
KR20160079129A (ko) 2016-07-05
AU2006291006A1 (en) 2007-03-22
EP1937065A4 (en) 2010-07-21
NL301339I2 (nl) 2025-09-16
CN101304656A (zh) 2008-11-12
FR25C1030I2 (fr) 2026-02-06
SI1937065T1 (sl) 2015-05-29
US20070060649A1 (en) 2007-03-15
CY2025023I2 (el) 2026-02-25
BRPI0615835B8 (pt) 2021-05-25
KR20150013952A (ko) 2015-02-05
TWI414510B (zh) 2013-11-11
US7709682B2 (en) 2010-05-04
AR058044A1 (es) 2008-01-23
KR20080046695A (ko) 2008-05-27
TW200804256A (en) 2008-01-16
BRPI0615835B1 (pt) 2020-04-22
BE2025C533I2 (enExample) 2026-02-02
EP1937065B1 (en) 2015-01-28
JP5467770B2 (ja) 2014-04-09
CY2025023I1 (el) 2026-02-25
FIC20253005I1 (fi) 2025-07-31
HUS2500034I1 (hu) 2025-09-28
US8669288B2 (en) 2014-03-11
WO2007033231A3 (en) 2007-10-11
LTPA2025530I1 (enExample) 2025-08-25
GT200600420A (es) 2007-05-08
HK1122699A1 (en) 2009-05-29
CA2622722C (en) 2016-04-19
HN2006032171A (es) 2011-03-15
HUE025185T2 (en) 2016-02-29
UY29791A1 (es) 2006-12-29
NZ566504A (en) 2010-11-26
US20110105616A1 (en) 2011-05-05
EP1937065A2 (en) 2008-07-02
BRPI0615835A2 (pt) 2011-05-31
AU2006291006B2 (en) 2012-09-13
WO2007033231A2 (en) 2007-03-22
DK1937065T3 (en) 2015-02-09
JP2009514797A (ja) 2009-04-09
LUC50018I1 (enExample) 2025-07-29
KR20180079468A (ko) 2018-07-10
CA2622722A1 (en) 2007-03-22
LUC50018I2 (enExample) 2026-05-05

Similar Documents

Publication Publication Date Title
CY2025023I2 (el) Νεα αλατα λυσινης παραγωγων 4- ((φαινοξυαλκυλ)θειο)-φαινοξυοξεικου οξεος
LTPA2020525I1 (lt) Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
CU24179B1 (es) SALES DE ÁCIDO MALEICO Y DE ÁCIDO SULFÚRICO DE (R)-3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CICLOPENTILPROPANITRILO
ATE537147T1 (de) Azabiphenylaminobenzoesäurederivate als dhodh- inhibitoren
ATE522624T1 (de) Identifizierung von krankheitserregern
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2470518T3 (da) Esterderivater af 2,5-furandicarboxylsyre og deres anvendelse som blødgørere
ATE538115T1 (de) Kondensierte anthranilsäureamidderivate als insektizide
BRPI0715617A2 (pt) Derivados do ácido fenoxifenilacético 4-substituído
DK2364308T3 (da) Pyrazinforbindelser som inhibitorer af Phosphodiesterase 10
NO20090578A (no) Farmasøytisk sammensetning inneholdende en tetrahydrofolsyre
BRPI1012198A8 (pt) sais de dissacarina, ácido difumárico, ácido di-1-hidróxi-2-naftoico e ácido mono-benzoico de 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il)metil) fenil) acetato de 4-(dimetilamino)butila
ATE509925T1 (de) Substituierte bicyclocarbonsäureamidverbindungen
ATE478849T1 (de) 4-anilinochinolin-3-carbonsäureamide als csf-1r- kinaseinhibitoren
DK1968949T3 (da) Forbedret fremgangsmåde til fremstilling af salte af 4-(benzimidazolylmethylamino)-benzamider
BRPI0922489A2 (pt) amida de ácido 4-(1,2,3,4-tetrahidroisoquinolina-2-il)-4-oxobutírico como modulares de kcnq2/3
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
DK1912647T3 (da) Quinolinderivater som antibakterielle midler
BRPI0921596A2 (pt) Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina
DK2076494T3 (da) Piperidin- eller piperazinsubstituerede tetrahydro-naphthalen-1-carboxylsyre-mtp-inhiberende forbindelser
DE602006015789D1 (de) Wässrige lösungen von optischen aufhellern
ATE530529T1 (de) 5-phenyl-nicotinsäureamid-derivate
DE602007003819D1 (de) Bindung von kohlenstoff-kohlenstoff-verbundstoffen mittels titancarbid
DK1650186T3 (da) Nye dicarboxylsyrederivater
ATE543797T1 (de) Quaternäre alpha-aminocarbonsäureamidderivate als modulatoren von spannungsabhängigen natriumkanälen